Hybrid clinical trial models aren’t new, but they have grown from a novelty to a necessity over the past decade.1 While the benefits of hybrid trials cannot be overstated, many decision makers still view it as a temporary measure. Others remain weary or unsure of how to take the first steps into hybrid decentralized studies, let alone embrace it on a wide scale.